Merck & Company Inc (MRK)vsVir Biotechnology Inc (VIR)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
VIR
Vir Biotechnology Inc
$10.62
+0.38%
HEALTHCARE · Cap: $1.93B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 21854% more annual revenue ($66.57B vs $303.23M). MRK leads profitability with a 4.8% profit margin vs -83.0%. VIR earns a higher WallStSmart Score of 56/100 (C).
MRK
Hold36
out of 100
Grade: F
VIR
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Intrinsic value data unavailable for VIR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Strong operational efficiency at 30.7%
Revenue surging 19582.0% year-over-year
Earnings expanding 58.5% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Smaller company, higher risk/reward
Weak financial health signals
ROE of -47.7% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : VIR
The strongest argument for VIR centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 19582.0% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : VIR
The primary concerns for VIR are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while VIR is a hypergrowth play — different risk/reward profiles.
VIR carries more volatility with a beta of 1.63 — expect wider price swings.
VIR is growing revenue faster at 19582.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
VIR scores higher overall (56/100 vs 36/100) and 19582.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Vir Biotechnology Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?